{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:24:45Z","timestamp":1723767885847},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1709","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved a 12.45% gel formulation of the anticholinergic drug sofpironium (Sofdra \u2013 Botanix) for treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients \u22659 years old.<\/jats:p>","DOI":"10.58347\/tml.2024.1709c","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:00:35Z","timestamp":1723741235000},"page":"133-134","source":"Crossref","is-referenced-by-count":0,"title":["Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,8,19]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T17:00:37Z","timestamp":1723741237000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1709c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":0,"journal-issue":{"issue":"1709","published-online":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1709c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}